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Abstract: The utility of adjuvant chemotherapy after surgical re-
section for early-stage non-small cell lung cancer (NSCLC) is now
well established. Although a number of randomized clinical trials
have demonstrated the efficacy of platinum-based chemotherapy in
the overall population treated, subset analysis, excepting Japanese
studies, has uniformly shown the greatest efficacy for patients with
stage II and III disease and the least benefit for patient with stage I
disease. We review data regarding adjuvant therapy of stage I
NSCLC from clinical trials performed in North America and
Europe. Pertinent trials from Japan are discussed elsewhere in this
issue.
(J Thorac Oncol. 2007;2: Suppl 3, S125–S127)
The role of adjuvant therapy for early-stage NSCLC hasevolved rapidly in the last 5 to 10 years. In 1995, a
meta-analysis of surgically resected NSCLC demonstrated a
statistically insignificant 5% survival advantage at 5 years
with the addition of adjuvant cisplatin-based chemotherapy.1
Several phase III studies performed after that time, notably
Eastern Cooperative Oncology Group (ECOG) 3590 (inter-
group 0115),2 the Big Lung Trial (BLT),3 and the Adjuvant
Lung Project Italy (ALPI)4 also failed to show a significant
benefit with adjuvant chemotherapy (Table 1).
In 2003, the positive results of the International Adju-
vant Lung Trial (IALT) were reported, demonstrating a
significant survival advantage at 5 years (HR 0.86) with the
addition of four cycles of cisplatin-based chemotherapy after
complete resection of stage I-III NSCLC.5 Although the study
was not stratified to evaluate results by stage, a trend toward
increased benefit for patients with stage II and III disease was
identified. Although in absolute terms the results mirrored the
1995 meta-analysis by showing only a modest benefit to
chemotherapy, it was considered a breakthrough and set the
stage for other studies to follow (Table 1).
Two additional adjuvant chemotherapy trials were re-
ported to be positive in 2004. The National Cancer Institute
of Canada (NCIC) JBR.10 intergroup trial randomized 482
patients with completely resected stage IB-IIB NSCLC to
four cycles of cisplatin and vinorelbine or observation.6 A
15% survival advantage was reported at 5 years (HR of 0.7)
with the addition of chemotherapy. The trial was stratified by
stage, and, in subset analysis, no benefit was noted for the
subset of patients with stage IB disease. However, the same
year, the preliminary results of Cancer and Leukemia Group
B (CALGB) trial 9633 were presented at the American
Society of Clinical Oncology (ASCO) meeting. This study of
344 patients with surgically resected stage IB NSCLC
showed improved failure-free survival and overall survival
for those receiving adjuvant carboplatin and paclitaxel versus
observation.7 Of note, this trial was closed early when an
interim analysis demonstrated a 12% survival advantage at 4
years (HR 0.62, P  0.01). In 2005, the ANITA trial
confirmed the overall benefit of adjuvant therapy. This study
of 840 patients with resected NSCLC, nearly equally bal-
anced between stages IB and IIIA, found a 9% overall
survival advantage at 5 years with four cycles of adjuvant
cisplatin and vinorelbine (HR 0.79, P  0.013).8 Again,
however, when analyzed by stage, no benefit was found for
the subset of patients with stage IB disease.
With the results of these positive trials, adjuvant che-
motherapy was established as the standard of care for com-
pletely resected, early-stage II–IIIA NSCLC. Each of the
positive trials cited above demonstrated improved survival in
stages II–IIIA in subset analysis. However, each was negative
in stage IB, with the exception of CALGB 9633, the only
study to specifically address this population. Nevertheless,
based on the initial CALGB results, stage IB has generally
been included in the overall recommendation for adjuvant
chemotherapy in early stage NSCLC.
NEW FINDINGS IN ADJUVANT
CHEMOTHERAPY
An update of CALGB 9633 presented at the 2006
ASCO meeting has further clouded the issue of adjuvant
chemotherapy in stage IB disease. Although failure-free sur-
vival still favors chemotherapy (HR 0.74, P  0.03), there is
no longer an overall survival benefit (HR 0.80, P  0.10).9
Because CALGB 9633 was the only trial in support of
adjuvant chemotherapy for patients with stage IB disease,
these updated results have altered opinions regarding this
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issue. A recent individual patient meta-analysis of the large
adjuvant trials conducted since the 1995 meta-analysis (ex-
cluding CALGB 9633) by Pignon et al. helps to put these
findings into perspective. This analysis found an overall 5.5%
survival advantage at 5 years (HR 0.84, P  0.001) for
adjuvant cisplatin therapy,10 thus reinforcing the need to
power adjuvant trials for this range of benefit. The stage IB
subset analysis trended toward benefit (HR 0.92) but failed to
reach statistical significance (95% CI, 0.73-0.95). This meta-
analysis also included a subset of patients with stage IA
disease, for whom a negative impact on survival for adjuvant
chemotherapy was suggested. These results provide support
for the position that any benefit of platinum-based adjuvant
chemotherapy in the overall population of stage IB disease is
small and would require a prohibitively large trial to be
detected. Further dividing patients in CALGB 9633 into those
with tumors smaller than 4 cm versus those greater than or
equal to 4 cm identified a higher-risk group for which
chemotherapy may be beneficial. In an unplanned subset
analysis, patients in CALGB 9633 with tumors of at least 4
centimeters (close to 100 patients in each arm) retained an
overall survival advantage (HR 0.66, P  0.04).9 The 74
patients in each arm with tumors smaller than 4 cm did not
differ in survival (HR 1.02, P  0.51).
Although the studies previously cited all consisted of
platinum-based therapy, the largest trials in stage I NSCLC
adjuvant therapy have been conducted in Japan with the oral
agent uracil-tegafur (UFT), given daily for 2 years. These
studies, detailed elsewhere in this issue of The Journal,
support this treatment approach for patients with adenocarci-
noma with stage I tumors at least 2 cm in size. Whether these
results can be extrapolated to patient populations outside
Japan remains undetermined.
MOVING FORWARD: INTEGRATION OF
TARGETED AGENTS INTO ADJUVANT THERAPY
Regardless of the benefits of adjuvant chemotherapy we
reviewed, it remains clear that the overall benefit is modest
and further improvements are needed. The recent introduc-
tion of molecular-targeted therapies in advanced-stage
NSCLC presents several opportunities for integration of these
agents into an adjuvant therapy paradigm. In particular, both
anti-angiogenic agents (e.g., bevacizumab in combination
with chemotherapy) and epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (e.g., gefitinib and erlo-
tinib) have demonstrated efficacy in advanced-stage NSCLC.
The role of each of these targeted strategies is now being
investigated in the adjuvant therapy setting.
Bevacizumab
E4599 evaluated carboplatin plus paclitaxel with or
without bevacizumab, an anti-vascular endothelial growth
factor (VEGF) antibody, in advanced-stage NSCLC, demon-
strating a median survival of 10.2 months versus 12.5 months
(P 0.007), favoring the bevacizumab-containing regimen.11
These results make the addition of bevacizumab to adjuvant
chemotherapy a compelling research question. ECOG 1505 is
the proposed American intergroup trial investigating the ad-
dition of bevacizumab to adjuvant chemotherapy (Figure 1).
Initially, the study was designed to include patients with
surgically resected stage IB-IIIA NSCLC, stratified by stage,
histology, gender, and chemotherapy regimen, with investi-
gators given the choice of one of four chemotherapy combi-
nations before randomization.
Given the updated CALGB 9633 data, the inclusion of
IB patients in E1505 has been reconsidered, and those pa-
tients with stage IB disease and tumors smaller than 4 cm will
TABLE 1. Adjuvant Chemotherapy Trials (excluding uracil-tegafur data)
Study Stage n
Chemotherapy
Regimen (s)
HR (relative
survival likelihood) P Value
E35902 II–IIIA 488 Cis/VP16 0.93 0.56
BLT3 I–III 381 Cis/4 options 1.02 0.90
ALPI4 I–III 1209 Cis/MVd 0.96 0.585
IALT5 I–III 1867 Cis/vinca or VP16 0.86 0.03
BR.106 IB–II 482 Cis/vinorelbine 0.70 0.012
CALGB9633-20047 IB 344 Carbo/paclitaxel 0.62 0.028
ANITA8 I–IIIA 840 Cis/vinorelbine 0.79 0.013
CALGB9633-20069 IB 344 Carbo/paclitaxel 0.8 0.10
LACE meta-analysis10 I–III 4584 Cisplatin doublet 0.89 0.0004
FIGURE 1. Planned North American Intergroup Adjuvant
Chemotherapy Trial.
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be excluded, along with patients with stage IA NSCLC. The
issue of chemotherapy regimen has also been reconsidered.
Outside of Japan, adjuvant therapy trials to date have uni-
formly used platinum-based chemotherapy regimens. Al-
though multiple different regimens have been used, all have
been cisplatin-based, with the exception of the CALGB
regimen of carboplatin-paclitaxel. IALT used cisplatin with
either etoposide or a vinca alkaloid.5 Both JBR.10 and
ANITA used cisplatin and vinorelbine.6,8 In view of the
updated CALGB data, the carboplatin-paclitaxel regimen will
also be excluded from the chemotherapy menu for this new
ntergroup adjuvant trial. Regimens included consist of cis-
platin plus either vinorelbine, docetaxel, or gemcitabine.
Gefitinib and Erlotinib
The EGFR is implicated in the development and pro-
gression of cancer and is expressed in many human epithelial
malignancies, including NSCLC.12,13 Several small molecule
inhibitors of EGRF, including gefitinib and erlotinib, are
selective EGFR-TKIs that produce objective response rates of
9% to 26% in previously untreated or previously treated
advanced-stage NSCLC.14–16 Recently, a phase III trial
(BR21) comparing erlotinib with placebo as a second- or
third-line therapy reported a survival benefit for the EGFR
inhibitor (HR 0.73).17 Importantly, this survival benefit was
not confined to objective responders or to a single gender or
histology. Postoperative adjuvant therapy trials were initiated
in Japan and North America (BR.19) with gefinib but were
closed early in both cases: in Japan because of concerns
regarding gefitinib-induced interstitial lung disease (ILD),
and in the case of BR.19, because of the failure of gefitinib to
improve survival in the second-line therapy of advanced-
stage NSCLC. An ongoing phase III trial (RADIANT) is
comparing erlotinib with placebo in the adjuvant therapy of
early-stage NSCLC in patients determined to be EGFR-
positive by FISH and/or immunohistochemistry. Therefore, at
the present time, the role of EGFR-TKIs in adjuvant therapy
remains unclear.
CONCLUSIONS
Although adjuvant platinum-based chemotherapy after
surgical resection of early-stage NSCLC is now a standard of
care for stage II–IIIA NSCLC, it remains controversial
whether such treatment should be offered for patients with
stage IB disease, especially those with tumors smaller than
4 cm. There are as yet no data to support the use of similar
adjuvant therapies in stage IA disease. In view of these
conclusions, a uniform recommendation for adjuvant chemo-
therapy in the proposed phase III trial comparing surgery with
SBRT in stage I NSCLC cannot be made. Based on the
proposed guidelines for the new North American Intergroup
study (E1505), it would be reasonable to recommend against
adjuvant therapy in American patients with stage IA or IB
tumors smaller than 4 cm but to allow investigators to deliver
up to four cycles of adjuvant platinum-based chemotherapy
for those patients with stage IB tumors larger than 4 cm.
Finally, continued progress must be made. Clinical trials
investigating targeted therapies such as bevacizumab and
erlotinib are warranted and are planned or ongoing at this
time. Participation in these studies is encouraged.
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